| Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease (NCT05447494) | CANbridge (Suzhou) Bio-pharma Co., Ltd. | 2022-07-11 |
| A Gene Therapy Study in Patients With Gaucher Disease Type 1 (NCT05324943) | Spur Therapeutics | 2022-04-15 |
| A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy. (NCT06050967) | Hadassah Medical Organization | 2022-04-01 |
| Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease (NCT04055831) | Lysosomal and Rare Disorders Research and Treatment Center, Inc. | 2019-05-15 |
| Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy (NCT03950050) | Shaare Zedek Medical Center | 2019-03-01 |
| Prodromal Parkinsonian Features in GBA1 Mutation Carriers (NCT05253560) | Shaare Zedek Medical Center | 2017-05-16 |
| Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa) (NCT03333447) | CEN Biotech | 2017-01-17 |
| Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension (NCT02843035) | Genzyme, a Sanofi Company | 2017-01-04 |
| Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs (NCT04353466) | Shaare Zedek Medical Center | 2017-01-01 |
| Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) (NCT04120506) | Shaare Zedek Medical Center | 2016-01-10 |
| Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1) (NCT02583672) | University of Minnesota | 2015-09-01 |
| The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease (NCT02528617) | Baylor Research Institute | 2015-07-01 |
| Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease (NCT02067247) | Shaare Zedek Medical Center | 2014-02-01 |
| Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease (NCT02770625) | ISU Abxis Co., Ltd. | 2011-09-01 |
| A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE) (NCT00891202) | Genzyme, a Sanofi Company | 2009-11-01 |
| A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE) (NCT00943111) | Genzyme, a Sanofi Company | 2009-09-01 |
| A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients (NCT00813865) | Amicus Therapeutics | 2009-05-11 |
| A Screening Study Evaluating Disease Status of Gaucher Type I Patients (NCT00795197) | Genzyme, a Sanofi Company | 2008-12-01 |
| A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease (NCT00446550) | Amicus Therapeutics | 2008-06-11 |
| An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease (NCT00635427) | Shire | 2008-03-13 |
| Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease (NCT00553631) | Shire | 2008-01-29 |
| A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy (NCT00433147) | Amicus Therapeutics | 2007-03-23 |
| A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease (NCT00430625) | Shire | 2007-02-15 |
| A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients (NCT00358150) | Genzyme, a Sanofi Company | 2006-06-01 |
| Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease (NCT00319046) | Actelion | 2006-02-01 |
| Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease (NCT00364858) | Genzyme, a Sanofi Company | 2001-12-01 |